Comparison of different doses of perineural dexmedetomidine as adjuvans to ropivacaine 0,67% for interscalene plexus block in association with 10 mg intravenous dexamethasone: a single center, double blinded, randomised controlled trial.

Status

Withdrawn

Phases

Phase 3Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506062-31-00

Acronym

azr2023001

Enrollment

260

Registered

2023-08-16

Start date

Unknown

Completion date

Unknown

Last updated

2023-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients scheduled for shoulder operations

Brief summary

Length of analgesia ( time untill intake of analgeticum )

Detailed description

Lenght of sensoric block, Length of motoric block, Percentage of postoperative nausea and vomiting first 48 hours, Time to recovery after anesthesia, Percentage of side effects during anesthesia ( hypotension, bradycardia ), Numeric Rating Scale score for pain the first 48 hours, Cumulative opioid consumption over 48 hours

Interventions

DRUGDexamethason CF 20 mg/ml

DRUGinjectievloeistof

DRUGRopivacaine 7.5 mg / ml solution for injection

DRUGNatriumklorid B. Braun 9 mg/ml innrennslislyf

DRUGlausn

DRUGDexdor 100 micrograms/ml concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Length of analgesia ( time untill intake of analgeticum )	—

Secondary

Measure	Time frame
Lenght of sensoric block, Length of motoric block, Percentage of postoperative nausea and vomiting first 48 hours, Time to recovery after anesthesia, Percentage of side effects during anesthesia ( hypotension, bradycardia ), Numeric Rating Scale score for pain the first 48 hours, Cumulative opioid consumption over 48 hours	—

Countries

Belgium

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026